Skip to main content
Curevac logo

Curevac — Investor Relations & Filings

Ticker · CVAC ISIN · NL0015436031 LEI · 724500BUT8GAG9LMYN56 F Manufacturing
Open in API
Filings indexed 14 across all filing types
Latest filing 2025-11-26 Declaration of Voting R…
Country NL Netherlands
Listing F CVAC

About Curevac

https://www.curevac.com/en/

CureVac is a global biopharmaceutical company specializing in the development of therapies based on messenger RNA (mRNA) technology. With over two decades of experience, the company engineers mRNA as a data carrier to instruct the human body to produce its own therapeutic proteins to combat a wide range of diseases. Its development pipeline focuses on creating transformative medicines, including prophylactic vaccines for infectious diseases and other therapeutic applications. CureVac collaborates with partners like GSK to advance its high-value mRNA programs, such as its seasonal influenza vaccine candidate.

Recent filings

Filing Released Lang Actions
CureVac Announces Voting Results of Extraordinary General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement from CureVac detailing the voting results of an Extraordinary General Meeting (EGM). It provides a breakdown of the votes cast for various agenda items, including the approval of a merger and the appointment of directors. This falls directly under the definition of a 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2025-11-26 English
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
Earnings Release Classification · 1% confidence The document is a press release titled 'CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates'. It contains detailed financial highlights, including revenue, operating profit, earnings per share, and cash position, as well as business updates regarding M&A activity and legal proceedings. As it is an initial announcement of quarterly financial results rather than a full interim report or a simple report publication notice, it is classified as an Earnings Release. 9M 2025
2025-11-24 English
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
Earnings Release Classification · 1% confidence The document is a press release titled 'CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates'. It contains key financial highlights, business updates, and condensed financial tables for the specified period. It is an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). Q2 2025
2025-08-15 English
CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech
Legal Proceedings Report Classification · 1% confidence The document is a press release announcing the resolution of patent litigation between CureVac, Pfizer, and BioNTech. While it mentions an acquisition, the primary focus is on the settlement of legal disputes and the associated financial payments. According to the filing definitions, documents detailing significant lawsuits or regulatory actions are classified as Legal Proceedings Reports (LTR).
2025-08-08 English
CureVac Announces Voting Results of General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled "CureVac Announces Voting Results of General Meeting" and details that shareholders voted in favor of all proposals, including board appointments. This content directly relates to the official outcomes of a shareholder meeting. The definition for Declaration of Voting Results & Voting Rights Announcements (DVA) is: "Official results from shareholder votes at any general meeting (AGM or EGM).". Although the meeting was an Annual General Meeting (AGM), the document's primary function is reporting the *results* of the vote, not providing the proxy materials (PSI) or general AGM information (AGM-R). Therefore, DVA is the most precise classification.
2025-06-24 English
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
Earnings Release Classification · 1% confidence The document is titled 'CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates'. It explicitly details financial figures (Revenues, Operating Result, Pre-Tax Loss) for the three months ended March 31, 2025, compared to 2024. This content structure—providing key financial highlights for a specific interim period (Q1)—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), as it is presented as a press release summarizing the results, rather than the full statutory filing. Furthermore, the document length is substantial (over 15,000 characters), indicating it contains more than just a brief announcement of publication (which would suggest RPA or RNS). Q1 2025
2025-05-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.